Tizanidine Tablets USP — Class III drug recall D-238-2013
Terminated recall by Dr. Reddy'S Laboratories, reported 2013-04-10, distributed nationwide. Labeling Illegible: There is a possibility that the bottle labels do not contain the strength of the product a
| Recall number | D-238-2013 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Dr. Reddy'S Laboratories, Bridgewater, NJ, United States |
| Recall initiated | 2013-03-19 |
| Classified | 2013-04-01 |
| Reported by FDA | 2013-04-10 |
| Terminated | 2014-02-06 |
| Distributed | Nationwide (US) |
| Quantity | 117,546 bottles |
| Reason classes | labeling, potency |
| NDC | 55111-0179, 55111-0179-03, 55111-0179-10, 55111-0179-15, 55111-0179-30, 55111-0180, 55111-0180-03, 55111-0180-10, 55111-0180-15, 55111-0180-30 |
| Lot numbers | 09/15, 10/15, C208625, C208984, C209113, C209369, C209680 |
Product
Tizanidine Tablets USP, 4 mg, 150-count tablets per bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachepally - 500 090 India; NDC 55111-180-15.
Reason for recall
Labeling Illegible: There is a possibility that the bottle labels do not contain the strength of the product as well as other printing details.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-238-2013. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.